Structure Model of Foresightful Export Oriented Strategies for Iran Pharmaceutical Industry: Using a Fuzzy DEMATEL Method

Keywords

Foresightful strategies, Iran pharmaceutical industry, Fuzzy DEMATEL, Structure model

How to Cite

Jassbi, A., Jafari, M., Mahdavi Mazdeh, M., & Maleki, M. (2021). Structure Model of Foresightful Export Oriented Strategies for Iran Pharmaceutical Industry: Using a Fuzzy DEMATEL Method. Iranian Red Crescent Medical Journal, 23(11). https://doi.org/10.32592/ircmj.2021.23.11.1113

Abstract

Background: Export orientation is one of the main approaches in developing Iran's pharmaceutical industry as a key health-related part of industries. It is necessary to identify, formulate and implement some foresightful strategies and strategic plans toward adopting the export approach in the Iran pharmaceutical industry.

Objectives: This paper aims to identify, prioritize and develop a structure model of foresightful export-oriented strategies and strategic plans for Iran's pharmaceutical industry.

Methods: Data gathering for identifying strategies conducted through literature review and some interviews with pharmaceutical industry experts analyzed through qualitative content analysis. Then fuzzy DEMATEL technique is used to prioritize and develop cause and effect and structure the model of identified strategies.

Results: Policy modification, privatization, smart self-sufficiency in production, knowledge management in both national policy and industry firm's levels, and quality improvement in all aspects of production and products were identified as foresightful export-oriented strategies and plans for Iran pharmaceutical industry.

Conclusion: Privatization is the most effective and important foresightful export-oriented strategy in Iran's pharmaceutical industry.

https://doi.org/10.32592/ircmj.2021.23.11.1113

References

  1. Rasekh HR, Mehralian G, Vatankhah-Mohammadabadi AA. Situation analysis of R & d activities: an empirical study in Iranian pharmaceutical companies. Iran J Pharm Res  IJPR. 2012;11(4):1013-1025. doi:10.22037/IJPR.2012.1192.
  2. Yusefzadeh H, Rezapour A, Lotfi F,  Ebadifard Azar F,  Nabilo B, Abolghasem Gorji H,  Hadian M,  Shahidisadeghi N,  KaramiA,et al. A Study of Comparative Advantage and Intra-Industry Trade in the Pharmaceutical Industry of Iran. Glob J Health Sci. 2015;7(6):295-307. doi:10.5539/gjhs.v7n6p295.
  3. Shabaninejad H, Madani H, Amineh ZA, Doostzadeh E. A framework for evaluation of pharmaceutical industry development in developing countries: Evidence from Iran. Asian J Pharm Clin Res. 2016;9(5):50-54. doi:10.22159/ajpcr.2016.v9i5.10099.
  4. Kian MJ, Hadian M, Ghaffari S. Factors affecting pharmaceutical industry enforcements in Iran and selected countries. Arch Pharm Pract. 2020;11(S4):95-102.
  5. Yousefi N, Mehralian G, Rasekh HR, Yousefi M. New product development in the pharmaceutical industry: Evidence from a generic market. Iran J Pharm Res. 2017;16(2):831-843. doi:10.22037/IJPR.2017.2058.
  6. Cheraghali AM. Trends in Iran Pharmaceutical Market. Iran J Pharm Res IJPR. 2017;16(1):1-7. doi:10.22037/ijpr.2017.2165.
  7. Mehralian G, Shabaninejad H. The importance of competitiveness in new internationalized and competitive environment of the pharmaceutical industry. Iran J Pharm Res. 2014;13(2):351-352. doi:10.22037/IJPR.2014.1519.
  8. Varmaghani M, Hashemi-Meshkini A, Abdollahiasl A, et al. An overview to pharmaceutical financing in Iran. J Pharmacoeconomics Pharm Manag. 2017;2(1/2):45-49.
  9. Azbari ME, Olfat L, Amiri M, Soofi JB. A Network Data Envelopment Analysis Model for Supply Chain Performance Evaluation: Real Case of Iranian Pharmaceutical Industry. Int J Eng Prod Res. 2014;25(2):125-137.
  10. Karbassi Yazdi A, Muneeb FM, Wanke PF, Figueiredo O, Mushtaq I. Critical Success Factors for Competitive Advantage in Iranian Pharmaceutical Companies: A Comprehensive MCDM Approach. Math Probl Eng. 2021:1-17. doi:10.1155/2021/8846808.
  11. Kazemi M, Moghimi SM, Pourezzat AA. Identifying dynamic capabilities in pharmaceutical industry by Grounded theory (GT). J Futur Manag Res. 2019;30(117):1-11.
  12. Schreier M. Qualitative Content Analysis. In: The SAGE Handbook of Qualitative Data Analysis. SAGE Publications; 2014:170-184. doi:10.4135/9781446282243.n12.
  13. Schilling J. On the pragmatics of qualitative assessment designing the process for content analysis. Eur J Psychol Assess. 2006;22(1):28-37. doi:10.1027/1015-5759.22.1.28.
  14. Chang B, Chang CW, Wu CH. Fuzzy DEMATEL method for developing supplier selection criteria. Expert Syst Appl. 2011;38(3):1850-1858. doi:10.1016/j.eswa.2010.07.114.
  15. Aly S, Vrana I. Evaluating the knowledge, relevance, and experience of expert decision-makers utilizing the Fuzzy-AHP. Agric Econ. 2008;54(11):529-535. doi:10.17221/264-agricecon.
  16. Li CW, Tzeng GH. Identification of a threshold value for the DEMATEL method using the maximum mean de-entropy algorithm to find critical services provided by a semiconductor intellectual property mall. Expert Syst Appl. 2009;36(6):9891-9898. doi:10.1016/j.eswa.2009.01.073.
  17. Mohammadfam I, Mirzaei Aliabadi M, Soltanian AR, Tabibzadeh M, Mahdinia M. Investigating interactions among vital variables affecting situation awareness based on Fuzzy DEMATEL method. Int J Ind Ergon. 2019;74:102842. doi:10.1016/j.ergon.2019.102842.